Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Wilms tumour (WT) is one of the common and curable childhood cancer types included in the Global Initiative for Childhood Cancer (GICC) to monitor progress. Local evidence is key to finding effective and sustainable solutions to local challenges to improve care and survival. Local evidence generated by the Wilms Africa project is summarised with recommendations for the future.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/pbc.31386 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Significant Impact of Treatment Abandonment on Survival of Children With "Common and Curable" GICC Index Cancers in Sub-Saharan Africa-A Multicenter Prospective CANCaRe Africa Study.
Pediatr Blood Cancer
September 2025
The Collaborative African Network for Childhood Cancer Care and Research, CANCaRe Africa, Blantyre, Malawi.
Background: The World Health Organization Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common, curable cancers. This study describes survival rates of five of these cancers in sub-Saharan Africa and assesses the impact of treatment abandonment (TxA).
Methods: This multicenter, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphoblastic leukemia (ALL), Wilms tumor (WT), retinoblastoma (RB), or Hodgkin lymphoma (HL), enrolled between January and December 2022 from seven hospitals in Malawi, Ethiopia (n = 2), Ghana, Kenya, Uganda, and Cameroon.
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
Nat Commun
June 2025
Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Relapsed and/or refractory acute myeloid leukemia (AML) post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. We previously reported that post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8 T cells engineered to express a Wilms Tumor Antigen 1-specific T-cell receptor (T) appeared to prevent relapse in high-risk patients. In this phase I/II clinical trial (NCT01640301), we evaluated safety (primary endpoint), persistence and efficacy (secondary endpoints) of EBV- or Cytomegalovirus (CMV)-specific T in fifteen patients with active AML post-HCT.
View Article and Find Full Text PDFPediatric Malignant Tumors in Malawi: A Diagnostic Report From the Kamuzu Central Hospital Pathology Laboratory 2011-2020.
Pediatr Blood Cancer
July 2025
University of North Carolina Project-Malawi, Lilongwe, Malawi.
Background: In 2011, a partnership between Kamuzu Central Hospital (KCH) and the University of North Carolina (UNC) led to the opening of the first diagnostic pathology laboratory in Lilongwe, Malawi's capital.
Procedure: A retrospective case series of malignancies diagnosed at the KCH-UNC pathology laboratory between 2011 and 2020 in pediatric and adolescent patients aged 0-18 years.
Results: Between 2011 and 2020, 12761 specimens were received from 5137 pediatric and adolescent patients.
Clinical Profile of Pediatric Solid Tumors: Experience From a Tertiary Care Center in Ethiopia.
Cancer Rep (Hoboken)
May 2025
Division of Pediatric Hematology/Oncology, The Herman and Walter Samuelson Children's Hospital at Sinai, Baltimore, Maryland, USA.
Background: Pediatric solid tumors are a significant health challenge worldwide, especially in low- and middle-income countries such as Ethiopia, where healthcare infrastructure is limited and treatment modalities are scarce.
Aims: This study aims to understand the epidemiological characteristics of these tumors and short-term treatment outcomes.
Methods And Results: A retrospective study spanning a period of 2 years and 8 months was conducted among all children below age 15 years admitted to St.
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
medRxiv
December 2024
Program in Immunology, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Acute myeloid leukemia (AML) that is relapsed and/or refractory post-allogeneic hematopoietic cell transplantation (HCT) is usually fatal. In a prior study, we demonstrated that AML relapse in high-risk patients was prevented by post-HCT immunotherapy with Epstein-Barr virus (EBV)-specific donor CD8 T cells engineered to express a high-affinity Wilms Tumor Antigen 1 (WT1)-specific T-cell receptor (T). However, in the present study, infusion of EBV- or Cytomegalovirus (CMV)-specific T did not clearly improve outcomes in fifteen patients with active disease post-HCT.
View Article and Find Full Text PDF